IMPACT OF TEBIPENEM-PIVOXIL ON THE INTESTINAL MICROBIOTA AND ON ESTABLISHMENT OF COLONIZATION WITH CARBAPENEM-RESISTANT KLEBSIELLA PNEUMONIAE IN MICE

Antimicrobial therapy has the potential to cause unintended adverse effects by promoting antibiotic-resistant bacteria. Therefore, as new antibiotics are developed there is a need to understand their potential to disrupt the indigenous microbiota of the colon and promote colonization by pathogens. Tebipenem pivoxil (Teb-piv), the first oral carbapenem, has potent in vitro activity against Enterobacterales pathogens, but requires combination with an appropriate β-lactamase inhibitor to achieve activity against Klebsiella pneumoniae carbapenemase and metallo-β-lactamase (MBL)-producing carbapenem-resistant Enterobacterales抗菌治疗可通过促进耐药菌增殖，引发非预期的不良反应。因此，随着新型抗生素的研发，亟需明确其是否会干扰结肠原籍微生物群，并促进病原菌定植。特比培南匹伏酯（Tebipenem pivoxil，简称Teb-piv）作为首款口服碳青霉烯类药物，对肠杆菌目病原菌具有强效体外抗菌活性，但需与适宜的β-内酰胺酶抑制剂联用，方可对产肺炎克雷伯菌碳青霉烯酶及产金属β-内酰胺酶（MBL）的碳青霉烯类耐药肠杆菌目发挥抗菌作用。